RENO, Nev., Oct. 2, 2012 /PRNewswire/ -- First Warning
Systems, Inc. celebrates Breast Cancer Awareness Month with the
release of a testimonial of Nedra
Lindsay's 19 year breast cancer survival account.
Nedra's story is one of chance. Present day recommended
breast cancer screening protocols are very similar to what they
were almost 20 years ago. Current protocols recommend mammographic
screening starting at age 40 unless there is a heightened
risk or family history. This video represents the power of
earlier, safer, and accurate screening beginning at an early age,
yielding a proactive approach to the discovery and management of
this devastating disease. It is now widely accepted that
identifying the disease in its earliest stages significantly
increases chances of survival. Nedra's story is a testament
to this proactive approach.
Nedra, a 24 year old nurse at Greene Memorial Hospital in
Xenia, OH, heard about a clinical
trial being conducted by Dr. Ron
Fletcher, Chief of Staff and Principal Investigator of a
study being conducted for the First Warning System. Her
friend had planned to participate in the study, but could not make
it. Nedra decided to substitute. The First Warning
System indicated tissue anomalies that were clearly abnormal and
that might be compatible with a cancerous condition.
Mammography was then performed and indicated cysts. Further
testing was performed, and ultimately a biopsy confirmed a very
aggressive form of cancer which was then treated.
Nedra is alive today because of the clinical trial and her
chance participation. "I would not be alive today, were it
not for this testing opportunity," according to Nedra. And as
Dr. Fletcher says, "Here is a young lady that would have waited
years and years for testing while a tumor kept growing, and
manifesting the potential to spread and might have been
incurable. I see First Warning as the potential to help
eliminate a potentially mortal threat by detecting that early
circumstance," adds Fletcher.
Please see the First Warning website to see Nedra's story.
About First Warning Systems Process
Temperature readings of breast tissue create
a dynamic cell chaos profile using 9,600
points of dynamic data which are correlated to
dysfunctional circadian genes. Multiple bioinformatics
algorithms compare the circadian gene protein
profiles to identify breast tissue abnormalities at
different stages of development of disturbed breast cancerous
cells. FWS delivers a report to the primary care physician with
industry leading 90% accuracy. The FWS process is the only
detection process that identifies abnormalities before a tumor
presents and can be used by a primary care physician.
About First Warning Systems
First Warning Systems, (FWS) founded in 2008, is based in
Reno, NV. FWS's principal
shareholder is Lifeline Biotechnologies, Inc. (OTC Market: LLBO).
FWS holds the exclusive development, manufacturing and marketing
worldwide license from Lifeline, to commercialize the intellectual
property. The FWS product line is a device and process that detects
breast tissue abnormalities leading to health risk assessment and
management and potentially, breast cancer. Three clinical trials
with over 650 participants have achieved proof of concept and
superior outcomes when compared to other diagnostic protocols.
FWS is planning a final, limited clinical trial and a 510k
device classification to validate the fourth generation of the FWS
product. FWS is preparing to apply for a Euro CE Mark to market in
the UK, EU and Russia markets. See
FWS' video, "Breast Cancer Tumor Progression" at
www.firstwarningsystems.com
For more information, contact: Jim
Holmes, CEO, 775-852-3222,
jholmes@firstwarningsystems.com
SOURCE First Warning Systems, Inc.